Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTFB.L Regulatory News (MTFB)

  • There is currently no data for MTFB

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Exercise of Warrants

7 Mar 2018 12:29

RNS Number : 9943G
Motif Bio PLC
07 March 2018
 

Exercise of Warrants

 

Motif Bio plc (AIM/NASDAQ: MTFB), a clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced that it has received notification from a warrant holder to exercise warrants representing 178,571 ordinary shares of 1p each ("Ordinary Shares") in the Company at an exercise price of 32.2p per warrant for total consideration of £57,499.86.

 

Application has been made for the 178,571 new Ordinary Shares to be admitted to trading on AIM ("Admission"), which is expected to occur at 8.00 a.m. on 13 March 2018. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares. The Company does not hold any Ordinary Shares in treasury. Following Admission, and for the purposes of the Disclosure Guidance and Transparency Rules, the Company's total issued share capital will consist of 264,276,443 Ordinary Shares. Shareholders may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the issued share capital of the Company.

 

For further information, please contact:

 

Motif Bio plc

info@motifbio.com

Graham Lumsden (Chief Executive Officer)

 

 

 

 

Peel Hunt LLP (NOMAD & BROKER)

 

+ 44 (0)20 7418 8900

Dr Christopher Golden

 

Oliver Jackson

 

 

 

 

Northland Capital Partners Limited (BROKER)

 

+44 (0)203 861 6625

David Hignell/John Howes/Rob Rees

 

 

 

 

 

 

Walbrook PR Ltd. (UK FINANCIAL PR & IR)

 

+44 (0) 20 7933 8780 / motifbio@walbrookpr.com

Paul McManus/Helen Cresswell/Lianne Cawthorne

 

 

 

 

MC Services AG (EUROPEAN IR)

 

+49 (0)89 210 2280

Raimund Gabriel

raimund.gabriel@mc-services.eu

The Trout Group (US IR)

+1 (646 )378-2963

Meggie Purcell

mpurcell@troutgroup.com

Russo Partners (US PR)

+1 (858) 717-2310 +1 (212)845-4272

David Schull

david.schull@russopartnersllc.com

Travis Kruse, Ph.D.

travis.kruse@russopartnersllc.com

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCSSIFEWFASEED
Date   Source Headline
7th Mar 201912:07 pmRNSSecond Price Monitoring Extn
7th Mar 201912:02 pmRNSPrice Monitoring Extension
19th Feb 20197:00 amRNSConference Call and Webcast
18th Feb 20197:00 amRNSAmendment Agreement with Hercules Capital
15th Feb 20194:28 pmRNSHolding(s) in Company
15th Feb 20194:26 pmRNSHolding(s) in Company
14th Feb 20197:00 amRNSComplete Response Letter from the FDA
5th Feb 20197:00 amRNSExercise of Warrants
23rd Jan 20194:31 pmRNSExercise of Warrants
1st Nov 20184:40 pmRNSSecond Price Monitoring Extn
1st Nov 20184:35 pmRNSPrice Monitoring Extension
31st Oct 20187:00 amRNSJefferies London Healthcare Conference
30th Oct 20184:35 pmRNSPrice Monitoring Extension
16th Oct 20184:40 pmRNSSecond Price Monitoring Extn
16th Oct 20184:35 pmRNSPrice Monitoring Extension
3rd Oct 20188:01 amRNSMotif Bio Presents New Iclaprim Data at IDWeek
28th Sep 20187:01 amRNSMotif Bio Notes Statement from Amphion Innovations
25th Sep 20187:00 amRNSHalf-year Report
20th Sep 20187:00 amRNSUpcoming Scientific Conferences
5th Sep 20187:00 amRNSIclaprim Data presented at ESCMID/ASM Conference
29th Aug 20184:35 pmRNSPrice Monitoring Extension
21st Aug 20187:15 amRNSMotif Bio notes statement from Amphion Innovations
17th Aug 20187:00 amRNSIclaprim Data at ESCMID/ASM Conference
14th Aug 20184:49 pmRNSHolding(s) in Company
14th Aug 20184:48 pmRNSHolding(s) in Company
14th Aug 20187:00 amRNSFDA Acceptance of New Drug Application
9th Aug 20187:00 amRNSInvestor Events in August and September
8th Aug 20187:00 amRNSNotice of Allowance for Two U.S. Iclaprim Patents
2nd Aug 20184:35 pmRNSPrice Monitoring Extension
3rd Jul 20184:48 pmRNSHolding(s) in Company
3rd Jul 20187:00 amRNSDirectorate Change
26th Jun 201811:57 amRNSExercise of Stock Options
19th Jun 20181:58 pmRNSResult of AGM
14th Jun 20187:00 amRNSMotif Bio Submits NDA for Iclaprim
11th Jun 201811:41 amRNSHolding(s) in Company
11th Jun 20187:00 amRNSMotif Bio present New Iclaprim Data at ASM Microbe
8th Jun 20185:08 pmRNSHolding(s) in Company
31st May 20187:00 amRNSJefferies Global Healthcare Conference
25th May 20184:04 pmRNSHolding(s) in Company
24th May 20184:39 pmRNSHolding(s) in Company
23rd May 20185:42 pmRNSHolding(s) in Company
23rd May 20187:00 amRNSMotif Bio notes statement from Amphion Innovations
17th May 20182:24 pmRNSResult of Placing
17th May 20189:55 amRNSProposed Placing to raise approximately £10m
9th May 20187:00 amRNSAppointment of Vice President,Clinical Development
8th May 20187:00 amRNSMotif Bio to Present Iclaprim Data at ASM Microbe
1st May 20187:00 amRNSREVIVE-2 Study Results Published in Journal
19th Apr 20187:00 amRNSNew Iclaprim Data being Presented at ECCMID 2018
17th Apr 20184:40 pmRNSSecond Price Monitoring Extn
17th Apr 20184:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.